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Proof that percutaneous closure of the patent foramen ovale (PFO) is superior to medical treatment is still incomplete. Paradoxical
embolism is a rare event occurring over decades rather than years. None of the 4 randomized trials published carried enough
patients or was followed up for long enough to reach superiority endpoints. All data, however, point to a benefit of PFO closure. Free
wall erosion (exceedingly rare) and triggering of atrial fibrillation (in about 1% of patients) are the only noteworthy complications.
They are outweighed by the supposedly prevented events of paradoxical embolisms, such as stroke, transient ischemic attacks,
myocardial infarctions, or other systemic embolisms. Medical treatment with perhaps the exception of lifelong oral anticoagulation
provides less protection. During a 10-year follow-up of a comparative study the annual mortality was significantly lower in the
patients with PFO closure (0.4%) than in those with medical treatment (1.1%, 𝑃 < 0.03). PFO closure can be accomplished in less
than 1 hour with immediate resumption of physical activity. It represents thus a kind of mechanical vaccination.
1. Introduction
Thepatent foramen ovale (PFO) has been recognized for over
a century as a plausible cause of stroke permitting paradoxical
embolism of a per se rather innocuous small venous clot that
would go clinically unnoticed if it embolized to the lungs
where it would be lysed by intrinsic fibrinogen activators in
a day or two [1]. Percutaneous closure of atrial septal defects
(ASDs) preceded percutaneous coronary intervention (PCI)
by a couple of years when it was first described in 1974 [2].
PCI found an almost immediate resounding echo being to
date considered the origin and the main representative of
interventional cardiology. PFO closure only caught modest
attentionwhen it was described as a derivative of ASD closure
in 1992 [3].
While the initial devices were far fromperfect, the clinical
introduction of the Amplatzer PFO occluder (APO) in 1997
by Kurt Amplatz and the author on September 10, 1997
(Figure 1), provided a user-friendly, technically highly suc-
cessful, and particularly safe method that has prevailed since
without any basic changes [4]. The only truly competitive
techniques are those that copied the principle of the APO.
2. Technique of PFO Closure
The technique developed by the inventor and the author
is very straightforward and stripped to the bare essential.
In particular, there is no intraprocedural echocardiography
involved in contrast to the policy of most centers. While
additional imaging has a potential to enhance safety and
quality, it also harbors additional risks, for example, by
prolonging the procedure which my engender clot-forming
in the indwelling gear.
All that is required is a set consisting of a TorqVue sheath
with its obturator, a pusher cable, a short loader sheath,
and a Y-connector with adjustable fitting. The 9 French (F)
size sheath fits all APOs except for the 40/40mm cribriform
ASD occluder which is the largest member of the Amplatzer
device families predestined for PFO occlusion (Figure 2).The
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Figure 1: Kurt Amplatz (left) and Bernhard Meier (right) on the
occasion of the world’s first closure of a patent foramen ovale using
an Amplatzer PFO occluder (insert) on September 10, 1997, in
Switzerland.
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8 French
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Figure 2: Family of Amplatzer PFO occluders. The right/left
numbers indicate the diameters of the left and right disk, respectively
(different in some devices). The French size indicates the minimal
inner lumen of the required sheath (1F = 0.3mm). The double
(cribriform) occluders are also predestined for cribriform atrial
septal defects.
occluder itself consists of a nitinol mesh double disk with a
thin and stretchable waist with polyethylene (Dacron) inlays.
While the nitinol is not absorbable and a permanent implant,
the Dacron fabric inlays enhance tissue ingrowth before they
are resorbed. While the original size with a 25mm right disk
and 18mm left disk diameter (Figure 1) remained the most
common, more sizes have been added (Figure 2).
The patient does not usually need sedation. A bolus
of 5,000 units of heparin is given. After local anesthesia
of the groin a regular 0.035 inch U-shape tip guidewire is
introduced through a puncture needle. In about half of the
cases the wire will readily pass through the PFO into the
left atrium. If not, a curved catheter (ideally multipurpose
shape) placed at the level of the diaphragmwill direct the wire
medially. If the PFO still cannot be passed, it is negotiated
with the catheter alone and if that fails with the leading wire
after straightening the U-tip. Occasionally it will be necessary
to inject contrast medium to the direction where the PFO
is suspected to learn more about anatomy before passing
the PFO. A typical situation for that would be a PFO that
consists only of a small hole in one of the corners of the initial
foramen. In this case it will be necessary to guide the wire to
a sharp turn once it has entered the PFO tunnel.
Next the device is prepared by screwing it loosely onto
the pusher cable and retracting it in a water bath into the
short loading sheath to avoid trapped air bubbles. It is wise
to push it out of the loading sheath just once and retract it
back while staying under water. Repeated loading maneuvers
may temporarily impede the formation of flat disks.
The device is now introduced into the TorqVue sheath
which was advanced into the left atrium where the obturator
was slowly withdrawn allowing for back bleeding while
holding the outer end of the sheath as low as possible (usually
on the right side of the patient’s thigh). For this, the short
loading sheath is connected to the TorqVue sheath and the
device is advanced close to the tip of the sheath. Air that is
entering the sheath behind the device is of no concern at that
point. Before exiting the sheath the safe but slightly loosened
attachment of the screw is checked on fluoroscopy. If there is
no gap between the screw and its female counterpart on the
device, the pusher cable is turned leftward until it is felt that
the apparently too tightly fit screw is now freely turning. The
gap mentioned before will now appear on fluoroscopy.
The left half of the device is pushed out of the sheath up
to the middle waist so that the left disk can fully form. The
sheath and the pusher are then pulled back as a unit until
the left disk gets stopped at the septum. In a left anterior
oblique (LAO) projection the left disk will now appear in its
profile. From there on only the sheath will be pulled back
while gently advancing on the pusher cable. As soon as the
tip of the sheath has passed the screw, the entire set is pushed
against the septum to put the right disk into its proper place.
At this point the typical Pacman sign should be apparent in
the LAO projection (Figure 3).
The stability of the position is checked with a strong
wiggle on the pusher cable and a dye injection delineating the
right atrial septal border in a projection showing the 2 disks
in profile and perfectly separating them (Figure 3). Then the
device is unscrewed and the final position is redocumented
with a right atrial dye injection after perhaps adjusting the
projection to see again the 2 disks in perfect profile and
completely separated.
The patient can well compress the femoral venous punc-
ture himself or herself as there is no risk of hematoma in a
supine person. The pressure in the femoral vein is 10mmHg
or less.The patient may even get up immediately but then the
pressure on the groin has to be increased to about 60mmHg
because of the weight of the blood column from the top of the
head to the groin.
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Figure 3: Correct placement of an Amplatzer PFO occluder ascer-
tained by the Pacman sign. The transesophageal echocardiogram at
the left is depicted in the projection usually used on fluoroscopy
during implantation. The septum secundum (SS) has to be bitten
into by the leftmore cranial parts of the occluder disks.This reminds
us of Pacman biting into a dot.
The patient receives a tablet each of acetylsalicylic acid,
100mg, and clopidogrel, 75mg, to continue the former daily
for 5 and the latter for 1 month. We usually perform a control
transesophageal echocardiography (TEE) about 1month after
stopping all medications, that is, at about 6 months.
No restrictions are asked for and even sports are permit-
ted immediately. Usually a transthoracic echocardiogram is
performed to document the device in place before the patient
leaves the hospital after an hour or so of surveillance.
Antibiotic coverage during the procedure is used in most
places, for example, by giving 1 g of a cephalosporin by
mouth before the procedure and another one a couple of
hours later.Most centers also recommendobserving the usual
prophylaxis against endocarditis at least for the first 2months.
3. Indications for PFO Closure
Table 1 depicts the potential indications for PFO closure
referenced in the literature today and expanded by personal
experience and data. Secondary prevention in the case of
a recurrent presumably paradoxical embolic event on treat-
ment with acetylsalicylic acid or oral anticoagulation is the
only indication unequivocally accepted worldwide.
In light of the ease and safety of PFO closure and the
compelling evidence of its efficacy in the prevention of several
types of events, it appearsmandatory to react to the first event
already. Even in case that the event was not related to the PFO,
the fact that the PFOwas closed without any untoward effects
(almost invariably the case) prevents the subject from any of
the PFO-mediated problems in Table 1 for good, resulting in
a net benefit.
The indication to close a PFO should not be subject to the
absence of other potential stroke causes or stroke facilitators
such as the ones listed in Table 2. To the contrary, PFO closure
should be the first thing to consider with any stroke as it is
one of the easiest causes for stroke to assess and the easiest to
remedy.
Table 1: Potential indications for PFO closure.
(i) Secondary prevention
(a) Stroke
(b) Transient ischemic attack
(c) Embolic myocardial infarction
(d) Peripheral embolism
(e) Decompression incident
(f) High altitude pulmonary edema
(ii) Primary prevention
(a) Aggravating PFO attributes
(1) Atrial septal aneurysm
(2) Eustachian valve
(3) Chiari network
(b) Prothrombotic state
(c) Deep vein thrombosis
(d) Pulmonary embolism
(e) Pacemaker/defibrillator electrodes
(f) Embolism-prone surgery
(1) Major orthopedic
(2) Cerebral in sitting position
(g) Planned pregnancy
(h) Carcinoid tumor
(i) Special congenital situations
(iii) Therapeutic
(a) Migraine (with aura)
(b) Platypnea orthodeoxia
(c) Provoked exercise desaturation
(d) Sleep apnea
(iv) Vocational or recreational
(a) Deep sea diver
(b) Mountain climber, highlander
(c) Brass musician
(d) Glass blower
(e) Tile setter
(f) Military jet
(g) Astronaut or commercial pilot driver
(h) Acrobat pilot
Prothrombotic predisposition is common in the general
population and should be a reason to close the PFO rather
than not to. Even if the predisposition is considered severe
enough to warrant lifelong oral anticoagulation, the throm-
botic risk with the possibility of paradoxical embolism should
still be considered high enough to warrant PFO closure.
4. Randomized Evidence for
the Effect of PFO Closure
A total of 4 randomized PFO closure trials have been pub-
lished so far. The first one pertained to the role of the PFO in
migraine and is calledMIST trial (Migraine Interventionwith
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Table 2: Ischemic stroke classification.
(i) Arterial occlusion
(a) Lacunar
(b) Intracerebral
(c) Vertebral
(d) Internal carotid
(e) Common carotid
(f) Brachiocephalic
(ii) Arterial embolus
(a) Plaque/ulcer/dissection
(1) Intracerebral
(2) Carotid
(3) Vertebral
(4) Brachiocephalic
(5) Ascending aortic
(iii) Cardiac embolus from
(a) Left ventricle
(b) Left atrium
(1) Left atrial appendage (atrial fibrillation)
(2) Left atrial foramen pouch
(c) Myxoma or other tumors
(d) Vegetation (septic embolus)
(iv) Paradoxical embolus
(a) Patent foramen ovale
(b) Atrial septal defect
(c) Pulmonary fistula
(v) Pulmonary venous bed embolus
(vi) Cryptogenic
STARFlexTechnology) [5]. In this European sham-controlled
single-blind randomized trial, patients with a documented
PFO and frequent migraine attacks not controlled with 2
or more classes of prophylactic drugs were screened and
enrolled by headache specialists to either have their PFO
closed or to undergo general anesthesia and receive a skin
nick in the groin without having a device implanted (sham-
control). The obsolete STARFlex device was used, one of the
devices with the poorest records among those that have been
used for PFO closure during the past 20 years. The follow-up
duration was 6 months. Of a total of 432 patients screened,
260 (60%) were found to have a PFO. This is clearly higher
than the prevalence of PFOs in the normal population which
could be explained by a common genetic background were it
not for the therapeutic effect of PFO closure evident in this
trial (albeit not to a significant degree) and in most other
respective nonrandomized reports. Women accounted for
85% of the patients and the average age was 45 years. Roughly
40% in the PFO closure group benefitted from a reduction
of headache days of at least 50% compared to roughly 20%
in the sham-control group. The P value was borderline.
Unfortunately the outcome of the MIST trial has since been
more often used as a reason not to close a PFO in the realm of
migrainewhile it should have been used to close it. First, there
was a clear trend for migraine improvement and, second, the
collateral benefit of protection against other more important
events should be taken into account. For instance, 1 of the 74
patients in the sham-control group suffered a stroke during
the 6-month follow-up. This points to the main reason why
PFOs are to be closed.
The CLOSURE I trial (Evaluation of the STARFlex Septal
Closure System in Patients with a Stroke and/or Transient
Ischemic Attack due to Presumed Paradoxical Embolism
through a Patent Foramen Ovale) in North America was the
first randomized trial to be published on PFO closure for
prevention of ischemic cerebral events [6]. This randomized
open-label superiority trial was hampered by a short follow-
up (maximum of 2 years) and the use of the deficient
STARFlex device. A total of 447 patients were randomized to
closure and 462 patients tomedical therapy, the kind of which
was left to the discretion of the physicians. The average age
was 46 years and the genders were balanced; as they were in
all respective trials.The predefined primary endpoint initially
defined as a reduction of stroke or transient ischemic attacks
(TIAs) from 6% to 3% over 2 years was changed in-flight
in light of the slow recruitment observed from 6% to 2% to
allow for a reduction to 800 patients. The observed primary
endpoint rates were 7.7% in the medical group and 5.8% in
the closure group and this was not statistically significant. In
addition, atrial fibrillation (AF) was observed in 6% in the
closure group versus 1% in the medical group. The majority
of these AF episodes, however, occurred in the first 2 weeks
and were clinically silent. None of the subgroup analyses
revealed a significant protection of PFO closure but none
hinted to inferiority of it, either. Presumably due to the
selection process and the poor performance of the STARFlex
device, the closure group in the CLOSURE trial performed
worse than the average performance of nonrandomized
comparative trials of PFO closure and the control group
performed better [7]. This explained the narrow difference.
The PC trial (Percutaneous Closure of Patent Foramen
Ovale in Cryptogenic Embolism) was the next we published
and had been the first to be started, about 12 years before
publication by the author and his group [8]. According
to what had been stated in the protocol, only the first 5
years of follow-up were analyzed. A total of 414 patients at
an average age of 45 years were randomized in countries
dispersed around the world to either closure of the PFO with
an APO or medical therapy with antiplatelet drugs or oral
anticoagulation as per discretion of the treating physician.
The projected primary endpoint of a reduction of the annual
recurrence rate of stroke, TIA, or peripheral embolism from
3% to 1% was not reached. However, there was a relative
stroke reduction of 80% (5 strokes in the control group and
1 stroke in the closure group) which in itself leaves no doubt
that medical therapy could at best be noninferior. Using the
stroke definition of the similar RESPECT trial (Randomized
Evaluation of Recurrent Stroke Comparing PFO Closure to
Established Current Standard of Care Treatment) [9], the
stroke rate was even 7-fold higher without a PFO closure.
Complications were extremely rare. AF was numerically but
not significantly more common in the closure group which is
explicable on the basis of mechanical irritation by the device.
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The RESPECT trial [9] randomized a total of 980 patients
in the United States of America to either closure of the
PFO with an APO or medical therapy with antiplatelet
drugs or oral anticoagulation at the discretion of the treating
physicians. Per protocol the follow-up was terminated when
25 strokes had occurred. By intention to treat analysis, 16
strokes had happened in the medical group and 9 in the
closure group with a P value of 0.08. Analyzed as treated,
the difference was significant (𝑃 = 0.007) with 16 strokes
in the control group and 5 in the closure group. Moreover,
predefined subanalyses showed a significant stroke reduction
in patients with a substantial PFO size or an atrial septal
aneurysm and when only the control patients treated with
antiplatelet agents were considered. Overall, the numbers
needed to treat to prevent a stroke were 70 and 24 at 2 and
5 years, respectively. Again, there was a numerically more
common occurrence of AF in the closure group without
statistical or clinical significance.
Lumping and meta-analyzing these 3 trials, the trend to
improved outcome with PFO closure compared to medical
therapy becomes stronger [10]. It reaches significance in
some meta-analyses [11]. Looking only at the APO studies,
significant improvement is documented [12].
There are 3 similar randomized trials still ongoing with a
projected total cohort of roughly 1,700 patients, that is, the
CLOSE trial in France (Closure of Patent Foramen Ovale
or Anticoagulants versus Antiplatelet Therapy to Prevent
Stroke Recurrence, NCT00562289), the DEFENSE PFO trial
in South Korea (Device Closure Versus Medical Therapy for
Secondary Prevention in Cryptogenic Stroke Patients with
High Risk Patent Foramen Ovale, NCT01550588), and the
REDUCE trial in Canada and Denmark (GORE HELEX
Septal Occluder and Antiplatelet Medical Management for
Reduction of Recurrent Stroke or Imaging-Confirmed TIA
in Patients with Patent Foramen Ovale, NCT00738894).
However, it is unlikely that any of these trials will be, in
itself, significant for the reasons of patient numbers and
follow-up duration cited above. They will add to the already
sizable amount of data collected. It is close to certain that
they will point to the same direction, that is, the advantage
of PFO closure. The question even arises whether further
randomization of patients with an index event suggesting
paradoxical embolism and a proved PFO is ethical still.
Recurrent events are more likely to occur in the control
group and they may encompass death, debilitating stroke,
or myocardial infarction and therefore be difficult to defend
considering the fact that they could have been prevented by a
simple procedure.
5. Nonrandomized, Personally Collected
Evidence for the Effect of PFO Closure
In terms of subjective improvement, 603 consecutive patients
with APO PFO closure mainly for reason of secondary
prevention after neurological events were assessed as per
their migraine status before and long term after PFO closure
[13]. Of note, there were no acute or follow-up complications
during an average of 5 ± 2 years. One patient suffered a
6%
6%
9%
45%
34%
85%Improvement
Cure
Improved by
>50%
Improved by
25%–50%
Unchanged
Worsened
Figure 4: Migraine status in 150 consecutive patients with Amplat-
zer PFO closure at an average of 5 ± 2 years of follow-up.The average
age of the patients was 51 ± 11 years, 61% were males, and 91% had
complete closure by 6-month transesophageal echocardiography.
Antiplatelet treatment had been stopped at the latest 6 months after
the intervention.
transient ischemic attack at 4 years, accounting for a 0.15%
event rate per year. Figure 4 depicts that migraine improved
dramatically. The long observation period excludes a mere
placebo effect.
The most compelling data recommending PFO closure
originate from the author’s group [14]. In the late nineties
308 consecutive patientswith an indexneurological event and
a PFO were randomly either sent for PFO closure or kept
on neurological outpatient treatment with either antiplatelets
or oral anticoagulation. A median of 10 years of follow-up
was available, looking at the total of 3,266 patient-years. A
statistically significant mortality reduction by PFO closure
was proved (0.4 versus 1.1% per year, 𝑃 = 0.03) when the time
after PFO closure was compared to that before or without
closure.This was driven by a roughly 50% reduction in stroke
rate (0.6% versus 1.2% per year, 𝑃 = 0.09) and an even
more drastically reduced rate of transient ischemic attacks
(Figure 5).
6. Outlook
Uncontestably, the PFO is a blemish with a small but definite
threat to health and even survival. As it is present in about
25% of the population, every PFO cannot be closed. Even
if the logistics were created to screen for a PFO and close
every PFO detected it might not be economically feasible.
Although a prevented stroke may save sufficient money to
pay for hundreds of PFO closures, some PFOs may have a
lifetime risk of hardly a percent to cause significant damage.
Moreover, currently reliable screening for PFO is only pos-
sible with TEE combined with a Valsalva maneuver and an
intravenous injection of echocardiographic contrast medium
(bubble test). If the targeted sensitivity is reduced to large
PFOs, such as those with an atrial septal aneurysm, opening
the gap with every heartbeat, or those with an Eustachian
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After closure (1,872 patient-years)
Without/before closure (1,394 patient-years)
0.4%
1.1%
0.6%
1.2%
0.5%
2.2%
0.0%0.1%
1.5%
4.6%
P < 0.001
HR = 0.34
P = 0.03
HR = 0.40
P = 0.09
HR = 0.51
P = 0.001
HR = 0.23
P = 0.25
HR = 0.17
Death Stroke TIA PE Death/stroke/TIA/PE
Figure 5: Annual event rates during a 10-year follow-up in 308
consecutive patients randomly assigned to PFO closure or medical
treatment. PE = peripheral embolism and TI = transient ischemic
attack.
valve directing the inflow from the inferior vena cava directly
on to the PFO, transthoracic echocardiography with a bubble
test suffices. Transcranial Doppler techniques to demonstrate
right-to-left shunts have been perfected over the past 20 years
but they also require an intravenous injection of some media
with a gaseous content. They are able to detect even small
shunts but they cannot define where the shunt occurs. The
same holds true for the most simple of all techniques, the
screening for ear lobe oxygen dip after a sustained Valsalva
maneuver without using any injection [15]. This is the only
test that could be used for screening school classes. Yet its
reliability, sensitivity, and specificity need to be tested further.
The PFO needs not to be looked for in childhood as
venous clots are virtually inexistent at very young age. Clots
tend to come into existence at middle age (with few excep-
tions) after which their incidence rises geometrically [16].
The common perception that the PFO is of less importance
in older and sick people has to be put into perspective. The
absolute PFO potential to cause harm steeply increases with
age (more clots in the venous blood) but the competitive
causes of ischemic events become more and more numerous
so that the PFO’s relative risk decreases. Some argue that
the PFO will shunt less frequently with age due to the
increasing left atrial pressure. However, Valsalva maneuvers
during defecation and micturition (men) also intensify with
age. Thus, closing the PFO makes sense even at high age and
with other stroke sources present. This concept has yet to be
adopted by medical attitudes guidelines and textbooks along
the modified stroke classification in Table 2.
PFO closure is the most straightforward, easy, and per-
haps even the most beneficial (net benefit) intervention in
today’s cardiology. It has to be in the repertory of every
interventional cardiologist. Health authorities should not
only ascertain reimbursement but also foster PFO closure.
There is still a long way to go to fill the gaps in secondary
prevention, not to mention exploiting the potential of PFO
closure in primary prevention in terms of a mechanical
vaccination.
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